4,769 reports of this reaction
3.3% of all INFLIXIMAB DYYB reports
#5 most reported adverse reaction
ARTHRALGIA is the #5 most commonly reported adverse reaction for INFLIXIMAB DYYB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 4,769 FDA adverse event reports linking INFLIXIMAB DYYB to ARTHRALGIA. This represents approximately 3.3% of all 142,758 adverse event reports for this drug.
Patients taking INFLIXIMAB DYYB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among INFLIXIMAB DYYB users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for INFLIXIMAB DYYB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 4,769 FDA reports for INFLIXIMAB DYYB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.3% of all adverse event reports for INFLIXIMAB DYYB, making it a notable side effect.
If you experience arthralgia while taking INFLIXIMAB DYYB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.